louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02747277: Analysis of B Cells From Autoimmune Individuals
Official title: Analysis of B Cells From Autoimmune Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lupus Erythematosus
Rheumatoid Arthritis
Type 1 Diabetes
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: National Center for Advancing Translational Sciences (NCATS)
First posted: 2016-04-21
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult males and females with a diagnoses of lupus erythematosus, rheumatoid arthritis, or type 1 diabetes

Brief summary: This observational study aims at finding out if individual with autoimmunity exhibit increased numbers of B cells that express two types (instead of one type) of antibodies, and if B cells of individuals genetically susceptible to autoimmunity display defects in the biological process of tolerance, which removes B cells that participate in autoimmunity.

Detailed description: Peripheral blood B cells of SLE patients are analyzed by flow cytometry to determine the frequency of B cells co-expressing immunoglobulin kappa an lambda light chains. This frequency is correlated to the disease activity.

Eligibility criteria: Inclusion Criteria:

* Adult Males and Females diagnosed with Lupus;
* Adult Females who are pregnant and diagnosed with:

  * lupus erythematosus
  * rheumatoid arthritis, or
  * type 1 diabetes.

Exclusion Criteria:

* Adult males or adult females treated with B-cell depletion therapies.

Primary outcomes:
measure: Frequency of kappa to lambda ratios of B cells in blood of autoimmune adults
timeFrame: 1 day
measure: Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Roberta Pelanda, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Peterson JN, Boackle SA, Taitano SH, Sang A, Lang J, Kelly M, Rahkola JT, Miranda AM, Sheridan RM, Thurman JM, Rao VK, Torres RM, Pelanda R. Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 Autoantibodies. Front Immunol. 2022 Feb 4;13:795209. doi: 10.3389/fimmu.2022.795209. eCollection 2022.
citation: Alves da Costa T, Peterson JN, Lang J, Shulman J, Liang X, Freed BM, Boackle SA, Lauzurica P, Torres RM, Pelanda R. Central human B cell tolerance manifests with a distinctive cell phenotype and is enforced via CXCR4 signaling in hu-mice. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2021570118. doi: 10.1073/pnas.2021570118.
Clinical trial NCT07007377: Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients
Official title: Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Flu-like Syndrome
FLU
Flu-like Symptoms
Vaccination
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2025-06-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with flu symptoms, which were vaccinated or not.

Brief summary: During the flu-like syndrome, the cardiovascular risk is increased, especially in the elderly. Understanding whether blood pressure assessment during an exercise test can aid in the understanding of patient outcomes, thereby improving prognostic ability in clinical practice, is the focus of the present study. Therefore, the aim of this study is to evaluate the hemodynamic response of adults with flu-like symptoms, both vaccinated and unvaccinated, and to conduct a 30-day follow-up for assessment. Patients who are indicated for an ergometric test and present with flu-like syndrome will be selected. We will inquire about their vaccination history and perform the ergometric test to evaluate test duration, arrhythmias, and ischemias


Eligibility criteria: Inclusion Criteria:

* flu-symptoms

Exclusion Criteria:

* recent orthopedic surgery

Primary outcomes:
measure: Can the ergometric test in flu-like syndrome help in the outcome analysis of unvaccinated patients?
timeFrame: 1 month
Secondary outcomes:
measure: Symptoms
timeFrame: 7 and 14 days after treadmill exercise test
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Clínica Pró-Coração
state: SP
Study officials:
References:
Clinical trial NCT04727177: Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia
Official title: Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Primary Dystonia
Transcranial Magnetic Stimulation
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: Hangzhou Normal University
First posted: 2021-01-27
Enrollment: 1
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this scheme, TMS treatment of Primary dystonia is planned by precise magnetic resonance positioning.


Eligibility criteria: Inclusion Criteria:

* Primary dystonia

Exclusion Criteria:

* None

Primary outcomes:
measure: Burke-Fahn-Marsden dystonia rating scale
timeFrame: Five days
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Zhejiang University
state: Zhejiang
Study officials:
affiliation: Zhejiang University
name: Jianhua Feng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05046977: Double Osteotomy for Deformity Correction in Pyle Disease
Official title: Double Osteotomy for Deformity Correction In Pyle Disease: Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pyle Disease
Keywords: Pyle disease
Genu valgus
Double Osteotomy
Deformity analysis
Functional outcome
Lead sponsor: Hawler Medical University
Sponsor class: OTHER
First posted: 2021-09-16
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Leg deformity is one of the features of Pyle disease( metaphyseal dysplasia). Correction of valgus deformity of the leg can be done after deformity analysis by double osteotomy so this study showed how double osteotomy can lead to better results than single osteotomy.


Eligibility criteria: Inclusion Criteria:

* Pyle Disease

Exclusion Criteria:

1. Smoking
2. Diabets Mellitus
3. Previous surgery on the limbs

Primary outcomes:
measure: Mechanical axis of lower limbs
timeFrame: This mechanical axes were assessed one year after surgery
measure: Knee injury and Osteoarthritis outcome score
timeFrame: This score was assessed one year post-operatively
Secondary outcomes:
Other outcomes:
Locations:
city: Erbil
country: Iraq
facility: Hawler medical University
Study officials:
References:
Clinical trial NCT03730077: FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas
Official title: Integrated Biomarker PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas Using a Novel PET/CT Tracer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Soft Tissue Sarcoma
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2018-11-05
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Subjects with known or suspected primary soft tissue sarcoma of the extremities may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age. Most participants will be receiving care at the clinical practices of the University of Pennsylvania Health System.

Positron emission tomography (PET/CT) imaging will be used to evaluate soft tissue sarcoma hypoxia using an investigational radiotracer, 18F-FMISO Subjects will also undergo an 18F-FDG PET/CT scan close to the time of their initial hypoxia PET/CT to compare in vivo measures of hypoxia to 18F-FDG uptake. The FDG PET/CT may be performed as part of standard clinical care or as a research scan. Both PET/CT scans will occur prior to starting new therapy.


Eligibility criteria: Inclusion Criteria:

1. Known or suspected soft tissue sarcoma seen on at least one type of standard imaging (e.g. CT, ultrasound, MRI, or 18F-FDG PET/CT)
2. At least 18 years of age
3. Subjects with local disease or advanced/metastatic disease will be eligible
4. Willing to consent to use of tissue from biopsy or surgery for the purposes of this study
5. Participants must be informed of the investigational nature of this study and be willing and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Females who are pregnant at the time of screening will not be eligible for this study; a urine pregnancy test will be performed at screening in women of child-bearing potential
2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
3. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study

Primary outcomes:
measure: Hypoxia in FMISO PET/CT
timeFrame: 2 years
Secondary outcomes:
measure: Marker of STS Hypoxia
timeFrame: 2 years
measure: Relationship of sarcoma hypoxia to glycolysis
timeFrame: 2 years
measure: Predictors of in vitro PLOD2 expression levels
timeFrame: 2 years
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT04530877: Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
Official title: Comparative Effectiveness of Exclusive Enteral Nutrition and Infliximab in Chinese Children With Active Crohn's Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Crohn's Disease
Exclusive Enteral Nutrition
Infliximab
Mucosal Healing
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2020-08-28
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: prospectively compared Exclusive Enteral Nutrition with Infliximab in the clinical outcomes, mucosal healing, nutrition improvements, adverse effects and gastrointestinal microbiota changes on Chinese Children With active Crohn's Disease


Eligibility criteria: Inclusion Criteria:

patients:

1. Pediatric active Crohn's disease ( CD) patients who were newly diagnosed at the Children's Hospital of Fudan University from October 2020 to Sep 2022，CD was diagnosed according to the Porto criteria and based on a combination of history, physical and laboratory examination, endoscopy with histology, and imaging of the small bowel (capsule endoscopy or magnetic resonance imaging or enhanced computerized tomography).
2. SES-CD\>4 and PCDAI \>10 at initial
3. For the patients whose fecal will be analyzed shouldn't take antibiotics or probiotics within the 1.5 months prior to the study and during the treatment.

healthy controls:

1. free medical history
2. had not taken antibiotics or probiotics within the 1.5 months prior to donate their fecal

Exclusion Criteria:

1. patients who had gene mutation or combined with other intestinal diseases such as tuberculosis or EB infection
2. for patients in the EEN group who could not finish the daily prescribed volume of formula for any reason; for the patients in the IFX group who could not finish the first 4 times IFX injection for any reason.
3. patients who were administered EEN, corticosteroids, immunosuppressive drugs, or biological agents prior to the study;
4. patients who could not attend consecutive follow-up sessions;

Primary outcomes:
measure: the number of patients who reach mucosal healing at the end of treatment in Exclusive enteral nutrition group
timeFrame: at the end of 8 week of treatment.
measure: the number of patients who reach mucosal healing at the end of treatment in Infliximab group
timeFrame: at the end of 14 week of treatment.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Gastroenterology, Pediatric Inflammatory Bowel Disease Research Center, Children's Hospital of Fudan University
name: Ying Huang, Dr
role: STUDY_CHAIR
References:
Clinical trial NCT06924177: UTSW NORC Pilot Spinal Cord Injury Dietary Program
Official title: Utilizing Dietician-guided Intervention to Combat Neurogenic Obesity in People With Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Obesity and Obesity-related Medical Conditions
Spinal Cord Injury, Chronic
Keywords: spinal cord injuries
obesity
insulin resistance
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this observational study is to learn about the effects of a 9-week dietician-guided program modified from the National Diabetic Prevention Program (modified DPP-diet) in people with spinal cord injury on body composition and insulin sensitivity.

The main question it aims to answer is:

Does 9 week modified DPP-diet reduce body fat percentage and insulin resistance?

Participants will:

Have 9 weeks of Telehealth visit with dietician certified in providing DPP. Visit the laboratory before, immediately and 9 weeks after completion of the modified DPP-diet.

Share with the researcher on the perceived benefit and obstacles in implementing the modified DPP-diet as part of their daily activities.


Eligibility criteria: Inclusion Criteria:

* age 18-65 years old
* have had SCI for more than one year
* not independently ambulatory
* primarily uses a wheelchair for mobility
* community-dwelling
* without comorbidities listed in the exclusion criteria

Exclusion Criteria:

* uncontrolled type 2 diabetes mellitus
* pregnancy
* active systemic disease, e.g., heart disease, real failure/insufficiency, multiple myeloma, lupus with nephropathy, sickle cell disease, symptomatic myasthenia gravis, poorly controlled hypo- or hyperthyroidism.

Primary outcomes:
measure: body fat composition
timeFrame: from enrollment to 9 weeks after completion of the modified DPP-diet program
measure: Homeostatic Model Assessment 2 for Insulin Resistance (HOMA2-IR)
timeFrame: from enrollment to 9 weeks after completion of the modified DPP-diet program
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
Study officials:
References:
Clinical trial NCT00495677: A Phase 2 Study Of PF-00232798 In HIV Positive Patients
Official title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HIV
Keywords: Treatment Experienced
Treatment Naive
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2007-07-03
Enrollment: 43
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.


Eligibility criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.

Exclusion Criteria:

* Patients who have received any experimental drug within the past four months (prior to the first dosing day of the study) or who have previously received another CCR5 antagonist.
* Patients with evidence of decompensated liver disease.

Primary outcomes:
measure: Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11
timeFrame: Baseline, Day 11
Secondary outcomes:
measure: Number of Participants With Time to Rebound of Human Immunodeficiency Virus (HIV) Viral Load
timeFrame: Day 1 up to Day 25
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0 hour (pre-dose) on Day 1 to 9; 0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10; Day 12, 13, 15 morning
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0 hour (pre-dose) on Day 1 to 9; 0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10; Day 12, 13, 15 morning
measure: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
timeFrame: 0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10
Other outcomes:
measure: Number of Participants With Viral Tropism and Resistance
timeFrame: Screening, pre-dose on Day 1; Day 11, 25
measure: Number of Participants With Chemokine Receptor 5 (CCR5) Delta 32 Genotyping and Immunophenotyping
timeFrame: Pre-dose on Day 1
Locations:
city: Frankfurt am Main
country: Germany
facility: Pfizer Investigational Site
city: Koeln
country: Germany
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00170677: Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Official title: Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Cancer
Lead sponsor: North Eastern German Society of Gynaecological Oncology
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 194
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.

Detailed description: Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy. None randomised study exists comparing a weekly topotecan application with an application on day 1-5. This study will compare the two applications in regard to: rate of complete or partial remissions, rate of toxicity, quality of life, progression free survival, overall survival.

Eligibility criteria: Inclusion Criteria:

* patients with histologically-confirmed ovarian cancer
* relapse within 6 month after primary therapy
* primary therapy with platin and taxan
* ECOG 0-2
* \>= 18 years
* leukocytes \>= 3.000/ µl
* platelet \>= 100.000/ µl
* neutrophil \>= 1.500/ µl
* written informed consent

Exclusion Criteria:

* earlier topotecan therapy
* simultaneous or planned radiotherapy
* secondary malignancy

Primary outcomes:
measure: Rate of CR and PR in each arm
timeFrame: every 12 weeks
Secondary outcomes:
measure: Toxicity of topotecan treatment
timeFrame: after each cycle
measure: Progression-free survival of both arms
timeFrame: every 12 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité Campus Virchow-Klinikum
Study officials:
affiliation: Charite University, Berlin, Germany
name: Werner Lichtenegger
role: STUDY_CHAIR
References:
Clinical trial NCT00231777: A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Official title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Post-Operative Nausea and Vomiting
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-10-04
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.


Eligibility criteria: Inclusion Criteria:

* Open abdominal surgery requiring 24 hour hospital stay
* General anesthesia
* Post-operative opioids
* ASA status of I-III

Exclusion Criteria:

* Patient exhibits evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or cardiovascular condition or congestive heart failure (CHF)
* Morbid obesity
* Patient is mentally incapacitated or has a significant emotional or psychiatric disorder

Primary outcomes:
measure: Number of Patients With Clinical Adverse Experiences (CAEs)
timeFrame: Baseline and 24 hours
measure: Number of Patients With Laboratory Adverse Experiences (LAEs)
timeFrame: Baseline and 24 hours
Secondary outcomes:
measure: Number of Patients With Drug-related CAEs
timeFrame: Baseline and 24 hours
measure: Number of Patients With Serious CAEs
timeFrame: Baseline and 24 hours
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04770077: Sniper Intubation for Training of Undergraduate Medical Student
Official title: Sniper Intubation for Training of Undergraduate Medical Student Randomized Controlled Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intubation;Difficult
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-02-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Undergraduate medical student

Brief summary: Students trained to focus on vocal cord before intubation

Detailed description: Student trained to spray vocal cords with 3 ml normal saline over 30 seconds before intubation then allow them to introduce endotracheal tube

Eligibility criteria: Inclusion Criteria:

* medical student

Exclusion Criteria:

* previous training on endotracheal intubation

Primary outcomes:
measure: Rate of successful intubation
timeFrame: Less than 120 seconds
Secondary outcomes:
measure: Number of attempts
timeFrame: 120 seconds
measure: Time to intubation
timeFrame: 120 seconds
Other outcomes:
Locations:
Study officials:
References: